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Abstract: Hydrogen peroxide (H2O2) is a main second messenger in oncogenic signaling networks
including the Ras and the growth factor receptor pathways. This is achieved predominantly through
the oxidation of redox-sensitive cysteine (Cys) residues in proteins resulting in changes to their
structure and function. We previously identified annexin A2 (ANXA2) as a redox regulatory protein
that plays an important cellular role during oxidative stress and also promoting tumorigenesis.
Here we investigated the role of ANXA2 in the regulation of H2O2-dependent signaling that drives
tumor progression. We show that depletion of ANXA2 leads to the enhanced activation of AKT
following either EGF/EGFR stimulation or oncogenic Ras transformation. The phosphatase and
tensin homologue (PTEN) protein negatively regulates the PI3K/AKT pathway. We demonstrate that
ANXA2 via its reactive Cys-8 residue, binds to PTEN and that the co-expression of PTEN and ANXA2,
but not ANXA2 Cys-8-Ala mutant, inhibits AKT phosphorylation on Ser 473. These results indicate
that ANXA2 is important for PTEN regulation within the PI3K/AKT signaling cascade. Furthermore,
we also reveal that ANXA2 inversely regulates the expression of the peroxidase, peroxiredoxin 2, in a
reactive oxygen species dependent manner.
Keywords: ANXA2; PTEN; PI3K/AKT; PRDX2; H2O2-dependent signaling
1. Introduction
Hydrogen peroxide (H2O2) plays a key role as a second messenger in cell signal transduction,
regulating cell proliferation, differentiation, migration and apoptosis [1–3]. This occurs primarily
through the oxidation of redox-sensitive (reactive) cysteine (Cys) residues within proteins by H2O2
which results in changes to their structure and function [4–6].
The epidermal growth factor receptor (EGFR) signaling is commonly up-regulated in
cancer, constituting an important pathway that regulates cell growth, survival, proliferation and
differentiation [7,8]. EGFR signaling is initiated by growth factor (e.g., EGF) binding which stimulates
dimerization and autophosphorylation of the receptor and subsequent downstream signaling by
phosphorylation/activation of tyrosine kinases and the concomitant inhibition of protein tyrosine
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phosphatases and the phosphatase and tensin homologue (PTEN) protein. Particularly, the activation of
the EGFR/PI3K/AKT pathway enables Rac to bind to and activate NADPH oxidase (NOX), ultimately
leading to the production of H2O2 [9,10]. H2O2 reversibly oxidizes and inactivates the main inhibitor
of the PI3K/AKT pathway, PTEN, allowing signal transduction to occur.
Another prominent H2O2-dependent signaling network associated with tumorigenesis is the
Ras pathway. Ras is a small G-coupled protein, whose activity is regulated by association with GTP
(promoted by Guanine Exchange Factors) generating an ON/active protein or GDP (promoted by
its own GTPase activity) constituting the OFF/inactive Ras. The constitutive activation of Ras has
been shown in approximately 30% of all cancers [11]. This occurs via mutation(s) of critical amino
acid residue(s) leading to the loss of Ras GTPase activity [12]. Ras regulates three critical signaling
networks, namely the Raf/MEK/ERK, PI3K/AKT and Ral-GDS pathways [12]. Ras/PI3K/AKT
signaling induces ROS production through the activation of the NOX regulatory subunit, Rac [13].
To balance the proliferative and survival advantage of moderate reactive oxygen species (ROS)
levels versus their damaging effect at high concentrations, cancer cells undergo a redox adaptation
process through the induction of the antioxidant response [14]. We identified a novel redox regulatory
protein, annexin A2 (ANXA2) that plays a key role in protecting cells from ROS induced death,
supporting both tumor growth and chemo-resistance [1,4,15]. ANXA2 can exist in the cells as a
monomer or a heterotetramer, where two ANXA2 molecules are bound together by a dimer of the
protein, S100A10 [16,17]. We previously demonstrated that the redox regulatory function of ANXA2 is
independent of S100A10 [1,14,15].
Here we show that ANXA2 depleted cells have enhanced phosphorylation of AKT upon
EGF/EGFR activation or transformation with oncogenic H-RasV12. We demonstrate that ANXA2,
via its reactive Cys-8 residue, can bind to the negative regulator of the PI3K/AKT signaling pathway,
PTEN. Our co-expression studies reveal that ANXA2 positively regulates PTEN activity, leading to the
inhibition of AKT. We also report for the first time that ANXA2 inversely regulates the peroxidase,
PRDX2 in a reactive oxygen species (ROS) dependent manner.
2. Results
2.1. ANXA2 Depleted Cells Show Enhanced AKT Activation Upon EGF/EGFR Stimulation
To investigate the role of ANXA2 in the regulation of EGF/EGFR signaling, we established
cancer cell lines depleted of ANXA2 (A549, HT1080 and MDA-MB-231 ANXA2 knockdown (KD)) and
respective controls (ANXA2 scramble). The treatment of ANXA2 KD cells with 15 nM EGF over time
led to a significantly higher activation of the PI3K/AKT signaling pathway, as assessed by enhanced
AKT phosphorylation at Thr308 and Ser473, and increased activation of the PI3K/AKT target protein,
P-4E-BPI in ANXA2 KD cells compared to their matched controls (Figure 1A,B and Supplementary
Materials Figure S1). This result was concomitant with increased proliferation of ANXA2 depleted
cells compared to their respective control cells following EGF treatment (Figure S2). We noted no
significant difference in the activation of the MAPK/ERK 1/2 signaling pathway, evaluated through
the phosphorylation of ERK 1/2, or PTEN expression in ANXA2 KD versus matched control cells
(Figure 1A,B and Supplementary Materials Figure S1).
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expressing H-RasV12 or the empty vector pBABE were grown in serum free media for 6 h or 16 h, 
respectively, after what cells were lysed and 20 µg of each protein extract was subjected to SDS-PAGE, 
transferred onto nitrocellulose membranes and analyzed by western blotting with the antibodies 
indicated. Results are representative of at least three independent experiments (n ≥ 3). 
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(HT1080) or for 16 h (MDA-MB-231) and either not reated (NT) or treated with 15 nM EGF for the times
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H-Ra V12 or the empty vector pBABE were grown in serum free media for 6 h or 16 h, respectively,
after what cells were lysed and 20 µg of each protein extract was subje ed to SDS-PAGE, transferred
onto nit ocellulose membrane and analyz d by western blotting with the an ibodies indicated. Result
are representative of at least three independent exp r ments (n ≥ 3).
2.2. ANXA2 Depleted Cells Show Enhanced AKT Activation Upon Oncogenic Ras Transformation
We next questioned if ANXA2 could play a role in the regulation of other oncogenic H2O2
inducing signaling pathways. We transformed HT1080 and MDA-MB-231 ANXA2 depleted and
control cells with oncogenic H-RasV12 or empty vector (pBABE). Cells depleted of ANXA2 and
over-expressing oncogenic H-RasV12 showed enhanced pSer473 AKT (Figure 1C,D) compared to
ANXA2 scramble cells over-expressing H-RasV12 or pBABE expressing cells. The activation of the
MAPK/ERK1/2 signaling pathway was significantly higher in H-RasV12 expressing cells compared
to controls (pBABE), however no differences were observed between ANXA2 depleted and matched
control cells (Figure 1C,D).
2.3. ANXA2 Via Cys-8 Residue Interacts with PTEN and Regulates Its Activity
We observed enhanced activation of AKT in ANXA2 depleted compared to control cells in
response to H2O2-dependent signaling. Based on these data we questioned if ANXA2 could
interact with PTEN, the main inhibitor of the PI3K/AKT pathway to indirectly regulate AKT activity.
To investigate this hypothesis we performed co-immunoprecipitation (Co-IP) assays using 293T cells
over-expressing WT or mutant ANXA2 Cys-8-Ala (ANXA2C8A) and PTEN. These results showed that
ANXA2 and PTEN interact via the reactive Cys-8 residue of ANXA2, since mutation of this residue to
alanine abolished the ANXA2/PTEN complex (Figure 2A).
Cancers 2019, 11, 492 4 of 15
Cancers 2019, 11, x 4 of 15 
 
To further investigate if and how ANXA2 regulated PTEN activity, we performed transient 
transfections using 293T cells, which express very low endogenous levels of ANXA2 and PTEN, with 
a combination of plasmids expressing either WT or mutant ANXA2 and/or PTEN proteins (Figure 
2B,C). These data demonstrated that expression of PTEN alone led to a slight decrease in AKT activity 
compared to control cells. However, AKT inhibition was more striking in cells over-expressing PTEN 
and ANXA2 (Figure 2B). Interestingly, expression of ANXA2 in 293T cells did not induce any changes 
in pSer473 AKT levels compared to control cells (293T pcDNA3) (Figure 2B). ANXA2 contains three 
cysteine (Cys) residues. To determine which ANXA2 Cys residue(s) were important for PTEN 
activity regulation we co-expressed PTEN with each mutant ANXA2 and evaluated the level of 
pSer473 AKT. The expression of ANXA2, ANXA2 Cys-132-Ala (ANXA2C132A) or ANXA2 Cys-334-Ala 
(ANXA2C334A) mutant proteins in 293 T cells over-expressing PTEN resulted in the inhibition of AKT, 
measured by reduced pSer473 AKT compared to control 293T cells transfected with empty pcDNA3 
vector (Figure 2C). However, co-expression of ANXA2C8A and PTEN did not inhibit pSer473 AKT 
levels compared to control cells (Figure 2C). Taken together these data indicate that the Cys-8 residue 
of ANXA2 plays an important role in maintaining PTEN activity. Interestingly, we observed that 
over-expression of the PTENC124S mutant enhanced pSer473 AKT compared to control cells. These 
results suggest that PTEN C124S might function as a dominant negative protein, having an opposite 
effect on AKT regulation compared to its WT counterpart protein. 
 
Figure 2. ANXA2 via its Cys-8 REDOX sensitive residue binds to PTEN and regulates its activity. (a) 
293T cells transfected with either empty vector; ANXA2 and PTEN-GFP expression plasmids or 
ANXA2 Cys-8-Ala and PTEN-GFP expression plasmids were grown in 60 mm plates. Cells were 
washed with PBS, lysed with Triton X-100 lysis buffer degassed for 1 h on ice. 300 µg of each cell 
lysate was incubated with the indicated antibodies for 1 h at 4 °C and then 50 µL of pre-washed 50% 
slurry protein G-Sepharose™ (GE Healthcare) was added for 1 h at 4 °C. Beads were washed four 
times with 300 µL of lysis buffer, resuspended with 20 µL 2× SDS-PAGE loading buffer, boiled for 10 
min, subjected to SDS-PAGE and analyzed by western blotting; 293T cells over-expressing (b) (1) 
empty vector, (2) PTEN, (3) ANXA2 or (4) ANXA2 and PTEN; or (c) (1) ANXA2 and PTEN, (2) ANXA2 
Cys-8-Ala and PTEN, (3) ANXA2 Cys-132-Ala and PTEN, (4) ANXA2 Cys-334-Ala and PTEN, (5) 
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ashed ith PBS, lysed ith Triton X-100 lysis buffer degassed for 1 h on ice. 300 µg of each cell
lysate as incubated with the indicated antibodies for 1 h at 4 ◦C and then 50 µL of pre-washed
50% slurry protein G-Sepharose™ (GE Healthcare) was added for 1 h at 4 ◦C. Beads were washed
four times with 300 µL of lysis buffer, resuspended with 20 µL 2× SDS-PAGE loading buffer, boiled
for 10 min, subjected to SDS-PAGE and analyzed by western blotting; 293T cells over-expressing
(b) (1) empty vector, (2) PTEN, (3) ANXA2 or (4) ANXA2 and PTEN; or (c) (1) ANXA2 and PTEN,
(2) ANXA2 Cys-8-Ala and PTEN, (3) ANXA2 Cys-132-Ala and PTEN, (4) ANXA2 Cys-334-Ala and
PTEN, (5) ANXA2 and PTEN Cys-124-Ser or (6) pcDNA3 (empty vector) were grown in 60 mm plates
in DMEM complete medium for 24 h. Cell lysates were prepared and 20 µg of each protein extract was
subjected to SDS-PAGE, transferred onto nitrocellulose membranes and analyzed by western blotting
with the antibodies indicated.
To further investigate if and how ANXA2 regulated PTEN activity, we performed transient
transfections using 293T cells, which express very low endogenous levels of ANXA2 and PTEN,
with a combination of plasmids expressing either WT or mutant ANXA2 and/or PTEN proteins
(Figure 2B,C). These data demonstrated that expression of PTEN alone led to a slight decrease in AKT
activity compared to control cells. However, AKT inhibition was more striking in cells over-expressing
PTEN and ANXA2 (Figure 2B). Interestingly, expression of ANXA2 in 293T cells did not induce
any changes in pSer473 AKT levels compared to control cells (293T pcDNA3) (Figure 2B). ANXA2
contains three cysteine (Cys) residues. To determine which ANXA2 Cys residue(s) were important for
PTEN activity regulation we co-expressed PTEN with each mutant ANXA2 and evaluated the level of
pSer473 AKT. The expression of ANXA2, ANXA2 Cys-132-Ala (ANXA2C132A) or ANXA2 Cys-334-Ala
(ANXA2C334A) mutant proteins in 293 T cells over-expressing PTEN resulted in the inhibition of AKT,
measured by reduced pSer473 AKT compared to control 293T cells transfected with empty pcDNA3
vector (Figure 2C). However, co-expression of ANXA2C8A and PTEN did not inhibit pSer473 AKT
levels compared to control cells (Figure 2C). Taken together these data indicate that the Cys-8 residue
of ANXA2 plays an important role in maintaining PTEN activity. Interestingly, we observed that
over-expression of the PTENC124S mutant enhanced pSer473 AKT compared to control cells. These
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results suggest that PTEN C124S might function as a dominant negative protein, having an opposite
effect on AKT regulation compared to its WT counterpart protein.
2.4. ANXA2 Regulates PRDX2 Expression
We noted that the same ANXA2 shRNAs led to more efficient knockdown of ANXA2 in
MDA-MB-231 cells compared to HT1080 or A549 cell lines (Supplementary Materials Figure S3). Since
ANXA2 is a H2O2 scavenger we investigated the ROS levels in these cells using 2′,7′-dichlorofluorescin
diacetate (DCF-DA) reagent. We observed higher levels of ROS in HT1080 and A549 ANXA2 KD cells
compared to their respective controls; interestingly, this was not observed in the MDA-MB-231 isogenic
pair (Supplementary Materials Figure S4). These data suggested that a more efficient depletion of
ANXA2 in the HT1080 or A549 cells likely resulted in a survival and/or proliferation disadvantage
due to excess ROS.
We next investigated the expression of the H2O2 scavengers, PRDX1 and PRDX2, in our isogenic
cell lines (Supplementary Materials Figure S5). We observed that ANXA2 depletion led to the
upregulation of PRDX2 in MDA-MB-231 cells compared to control cells (Supplementary Materials
Figure S5B), but this was not observed in HT1080 ANXA2 KD versus control cells (Supplementary
Materials Figure S5A). Of note, we were not able to detect PRDX2 in A549 cells (confirmed in
Supplementary Materials Figure S5A). We observed that cells depleted of ANXA2 and over-expressing
oncogenic H-RasV12 showed enhanced expression of PRDX2 compared to ANXA2 scramble cells
over-expressing H-RasV12 or pBABE expressing cells (Supplementary Materials Figure S5D,E).
To investigate if a more efficient depletion of ANXA2 in HT1080 cells could lead to increased
expression of PRDX2, we abrogated the ANXA2 gene in the HT1080 cells by CRISPR/Cas9. We noted
an approximately 5-6-fold increase in PRDX2 (but not PRDX1) expression in these cells compared
to HT1080 WT cells (Figure 3A,B and Supplementary Materials Figure S6A). We also established
MDA-MB-231 ANXA2 KO cells and observed the up-regulation of PRDX2 compared to control cells
(Supplementary Materials Figure S6B). Importantly, cells which reverted to the WT phenotype by
non-homologous recombination maintained similar levels of PRDX2 compared to MDA-MB-231 WT
cells (Supplementary Materials Figure S6B, lanes 2,5,6). In contrast, depletion of PRDX2 by shRNA
did not lead to up-regulation of ANXA2 in either MDA-MB-231, MCF7 or HCT-116 cancer cells
(Supplementary Materials Figure S7A–C).To investigate if the up-regulation of PRDX2 in HT1080
ANXA2 KO cells was regulated by ROS, we treated these cells with the antioxidant N-acetyl cysteine
(NAC). We observed the down-regulation of PRDX2 upon NAC incubation, indicative that regulation
of PRDX2 was ROS dependent (Figure 3C).
We next over-expressed ANXA2 in 293T cells and observed the down-regulation of PRDX2
compared to control cells transfected with pcDNA3 (Figure 3D). Interestingly, while a 24h exposure
with 100 µM H2O2 led to up-regulation of ANXA2, this oxidative stress induced the down-regulation
of PRDX2.
We further assessed the expression levels of ANXA2 and PRDX2 in a panel of cell lines by western
blotting (Figure 4A). This analysis showed that cells expressing high levels of ANXA2 have low levels
of PRDX2 and vice-versa, in agreement with the data described above. Cell signaling analysis showed
that the activation of the PI3K/AKT and MAPK/ERK 1/2 pathways was variable for each cell line
and did not show a clear correlation with the expression levels of either ANXA2, PRDX1-4 or PTEN.
We analyzed the distribution/localization of ANXA2 and PRDX2 in patient colon cancer tissue
sections (Figure 4B,D and Supplementary Materials Figure S8A). We noted that regions where the
expression of ANXA2 was high showed low to no expression of PRDX2 and vice-versa. Dual staining
for the nuclear marker hnRNP A2/B1 and ANXA2 showed the presence of cells in regions that have
low or no expression of ANXA2 (Supplementary Materials Figure S8B). Double staining for ANXA2
and S100A10 (ANXA2 binding partner [17]), showed co-localization of these proteins as predicted
(Figure 4C and Supplementary Materials Figure S8C).
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quantification. Error bars represent Standard Deviations. Statistical analysis was evaluated using two-
tailed Student’s t-test. In every case a p-value of less than 0.05 (*), less than 0.01(**) and 0.001 (***) was 
considered statistically significant; (c) HT1080 ANXA2 knockout sub-populations (ANXA2 KO #1; 
ANXA2 KO #2) or wild-type (WT) cells were grown in complete media either not supplemented (left 
panel) or supplemented with 5 mM NAC (right panel) for 48 h. After what cells were lysed and 20 µg 
of each protein extract was subjected to SDS-PAGE, transferred onto nitrocellulose membranes and 
analyzed by western blotting with the antibodies indicated; (d) 293T cells were transiently transfected 
with either pcDNA3 (empty) vector or pcDNA3-ANXA2 plasmids as indicated in the figure. 24 h after 
transfection these cells were either not treated or treated with 100 µM of H2O2 for 24 h. Cells were 
then lysed and 20 µg of each protein extract was subjected to SDS-PAGE, transferred onto 
nitrocellulose membranes and analyzed by western blotting with the antibodies indicated. Results are 
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Figure 3. ANXA2 regulates PRDX2 expression in a ROS dependent way. (a) HT1080 ANXA2 knockout
or WT cells were grown in complete media until 80% confluency. After what cells were lysed and
20 µg of each protein extract was subjected to SDS-PAGE, transferred onto nitrocellulose membranes
and analyzed by western blotting with the antibodies indicated. Cells were loaded in triplicates;
(b) Quantification analysis of PRDX2 immunoblots from (a). Quantification was performed using Image
J software. Tubulin immunoblot was used as a loading control for normalization of the quantification.
Error bars represent Standard Deviations. Statistical analysis was evaluated using two-tailed Student’s
t-test. In every case a p-value of less than 0.05 (*), less than 0.01(**) and 0.001 (***) was considered
statistically significant; (c) HT1080 ANXA2 knockout sub-populations (ANXA2 KO #1; ANXA2 KO
#2) or wild-type (WT) cells were grown in complete media either not supplemented (left panel) or
supplemented with 5 mM NAC (right panel) for 48 h. After what cells were lysed and 20 µg of each
protein extract was subjected to SDS-PAGE, transferred onto nitrocellulose membranes and analyzed
by western blotting with the antibodies indicated; (d) 293T cells were transiently transfected with either
pcDNA3 (empty) vector or pcDNA3-ANXA2 plasmids as indicated in the figure. 24 h after transfection
these cells were either not treated or treated with 100 µM of H2O2 for 24 h. Cells were then lysed and
20 µg of each protein extract was subjected to SDS-PAGE, transferred onto nitrocellulose membranes
and analyzed by western blotting with the antibodies indicated. Results are representative of three
independent experiments (n = 3).
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i (a) F7, 293T, ,
- B-231, HT1080, HCT1 6, HEK 293, TIME or U251 cells were lysed and 20 µg of each
protein extract was subjected to SDS-PAGE, transferred onto nitr cellulose membranes and alyze
by western blotting with the an ibodies indicated. This is a representative experiment of n > 3; Colon
tumor clinical samples wer flash frozen and section d using a cryostat. (b) Sections were th n H&E
stained or (c,d) fixed with methanol and immunostained with the antibodies nd cated, foll wed by
immunofluorescence staini g with secondary antibodies (ANXA2-gre n; S10 A10-red; PRDX2-red).
e perfor ed a ore thorough analysis of R S related genes in T1080 2 vs. T
and - B-231 X 2 vs scra ble cell lines using the u an xidative Stress RT2 Profiler
( iagen, anchester, ). The results depicted on Supple entary aterials Table S1 and Figure 5 ,B
did not sho substantial differences in the expression of R S related genes in the X 2 depleted
versus control cells. We further validated the expression of a subset of these genes that showed modest
differential expression changes in the ANXA2 depleted versus control cells by qRT-PCR (Figure 5C–F).
We observed a 1.5 fold up-regulation of PRDX2 in HT1080 and MDA-MB-231 ANXA2 KO compared
to control cells (Figure 5C,E). We observed a 1.5–2 fold induction of TrxRD2, and down regulation
of SCARA-3 in MD -MB-231 ANXA2 depleted compared to control cells (Figure 5E,F). We also
investigated the expression of ROS related proteins. We did not observe significant differences in the
expression of these proteins in ANXA2 depleted versus control cells, with the exception of PRDX2
(Figure 5G). Even though there were modest differences in the expression of CATALASE and TrxRD2
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genes in MDA-MB-231 ANXA2 KD compared to control cells we did not observe significant differences
at the protein levels. Of note we could not detect SCARA-3 protein in our extracts.
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shRNA2 or ANXA2 scramble cells were plated in 100 mm plates for 48 h. After what RNA extraction
was performed using the RNeasy mini kit (Qiagen, Manchester, UK) according to the manufacturer’s
instructions. A panel of 86 ROS dependent genes was analysed using the RT2 Profiler™ PCR Array
Human Oxidative Stress (Qiagen, Manchester, UK) according to the manufacturer’s instructions in
a LightCycler 96 instrument (Roche, Basel, Switzerland). (c) HT1080 ANXA2 KO #1; ANXA2 KO
#2 or WT; (d) HT1080 ANXA2 shRNA1; ANXA2 shRNA2 or ANXA2 scramble; (e) MDA-MB-231
ANXA2 KO #1; ANXA2 KO #2 or WT; (f) MDA-MB-231 ANXA2 shRNA1; ANXA2 shRNA2 or ANXA2
scramble cells were plated in 100 mm plates for 48 h. RNA extraction was performed using the RNeasy
mini kit (Qiagen, Manchester, UK) according to the manufacturer´s instructions. The gene expression
was determined by qRT-PCR using the One-step NZYSpeedy RT-qPCR Green kit (Nzytech, Lisbon,
Portugal) according to manufacturer’s instructions. The reaction was carried out using the Lightcycler
96 instrument (Roche, Basel, Switzerland). Gene expression levels were normalized to RPLP0 mRNA
using the 2−∆∆CT method (Livak KJ, Schmittgen TD). Error bars represent the standard deviation
obtained from three independent experiments. Statistical analysis was evaluated using two-tailed
Student’s t-test. In every case a p-value of less than 0.05 (*), less than 0.01(**) and 0.001 (***) was
considered statistically significant. (g) HT1080 ANXA2 shRNA1, ANXA2 shRNA2 and scramble (first
panel); HT1080 ANXA2 KO #1, ANXA2 KO #2 and WT (second panel); MDA-MB-231 ANXA2 shRNA1,
ANXA2 shRNA2 and scramble (third panel); MDA-MB-231 ANXA2 KO #1, ANXA2 KO #2 and WT
(fourth panel) cells were lysed and 20 µg of each protein extract was subjected to SDS-PAGE, transferred
onto nitrocellulose membranes and analyzed by western blotting with the antibodies indicated. Results
are representative of three independent experiments (n = 3).
3. Discussion
We previously identified ANXA2 as a redox regulatory protein that plays an important role during
oxidative stress and tumorigenesis [1]. With this work, we show for the first time, that depletion
of ANXA2 in cancer cells leads to enhanced activation of AKT in response to either EGF/EGFR
activation or oncogenic H-RasV12 transformation (Figure 1 and Supplementary Materials Figure
S1). The main inhibitor of the PI3K/AKT pathway, PTEN, contains reactive Cys residues in its
catalytic domain that can be readily oxidized by H2O2 inactivating its phosphatase function [18].
Our co-immunoprecipitation studies revealed that ANXA2 interacts with PTEN via ANXA2 Cys-8
residue (Figure 2A). These data in conjunction with the decreased activation of AKT observed in
ANXA2-containing compared to ANXA2 depleted cells upon H2O2-dependent signaling (Figure 1
and Supplementary Materials Figure S1) suggested that ANXA2 positively regulates PTEN activity.
Co-transfection studies using a combination of WT or mutants ANXA2 and PTEN expression plasmids,
confirmed that ANXA2 positively regulates PTEN inhibition of pSer473 AKT, in a Cys-8 residue of
ANXA2 dependent way (Figure 2C,D). Importantly, expression of ANXA2 alone in 293T cells did
not inhibit pSer473 AKT compared to 293T control cells (293T transfected with pcDNA3) (Figure 2B,
lane 3). These data suggest that ANXA2 does not directly regulate AKT activity, but does so via PTEN.
In this work we show for the first time that ANXA2 regulates the expression of the peroxidase,
PRDX2. In summary, we observed increased expression of PRDX2 upon depletion of ANXA2 in cancer
cells (Figure 5G and Supplementary Materials Figure S5). Of note, depletion of ANXA2 by shRNA
was insufficient to induce PRDX2 up-regulation in HT1080 ANXA2 KD cells or in MDA-MB-231 and
HT1080 pBABE cells, whose down-regulation of ANXA2 was less efficient compared to MDA-MB-231
ANXA2 KD cells (Figures S3 and S5). However, ANXA2 gene deletion in HT1080 and MDA-MB-231
cells led to the over-expression of PRDX2 compared to their respective WT cells (Figure 3, Figure 5
and Figure S6). Together these results suggest that a threshold for ANXA2 depletion is required to
trigger PRDX2 up-regulation in cancer cells. We demonstrated that PRDX2 regulation by ANXA2
was ROS dependent (Figure 3C). In this sense, a pronounced down-regulation of ANXA2 might
be necessary to induce sufficient accumulation of ROS leading to the subsequent up-regulation of
PRDX2 to compensate for the REDOX imbalance. In fact, cells over-expressing H-RasV12, which
leads to up-regulation of intracellular ROS, and depleted of ANXA2 showed a significantly higher
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expression of PRDX2 compared to cells expressing endogenous levels of ANXA2 and H-RasV12
(Supplementary Materials Figure S5). Analysis of intracellular ROS revealed that HT1080 and A549
ANXA2 KD cells have significantly higher levels of endogenous ROS compared to their respective
controls, while this was not observed in MDA-MB-231 ANXA2 KD cells (Figure S4). We observed
up-regulation of PRDX2 in the MDA-MB-231 ANXA2 KD compared to control cells, which did not
occur in the isogenic HT1080 or A549 cells (Supplementary Materials Figure S4). Taken together
these data support that up-regulation of PRDX2 in MDA-MB-231 ANXA2 KD cells leads to REDOX
homeostasis. Importantly, over-expression of ANXA2 led to down-regulation of PRDX2 in 293T cells
(Figure 3D), further supporting that ANXA2 inversely regulates the cellular expression of PRDX2.
Interestingly, when we depleted PRDX2 in cancer cells we did not observe up-regulation of ANXA2
(Supplementary Materials Figure S7). Analysis of ANXA2 and PRDX2 protein expression in a panel
of cell lines further showed an inverse relationship between ANXA2 and PRDX2 levels (Figure 4A).
Furthermore, expression patterns of ANXA2 and PRDX2 in colon cancer sections revealed that the
distribution of these two proteins is highly distinct. Areas with high ANXA2 expression display little to
no PRDX2 and vice-versa (Figure 4D and Supplementary Materials Figure S8A). PRDX2 and ANXA2
share many characteristics, including similar cellular distribution, high cytoplasmic abundancy with a
small fraction in the nucleus [19,20], calcium-dependent plasma membrane binding [17,21,22], lipid
raft co-localization [20,23], ion channels regulation [17,24,25], both directly inactivate H2O2 and are
recycled/reduced by the thioredoxin system [1,20] and both protect cellular DNA from oxidative
damage [15,26]. However, it is highly likely that ANXA2 and PRDX2 also have distinct functions and
interact with different proteins and targets within cells.
A study by Cao et al. found that PRDX1 binds to PTEN protecting it from oxidation-induced
inactivation and indirectly regulating AKT phosphorylation upon Ras signaling [27]. The authors also
show that PRDX2 was not able to bind to PTEN, which is in agreement with our results, demonstrating
that PRDX2 up-regulation is not able to impede the enhanced AKT phosphorylation observed upon
depletion of ANXA2 in cancer cells.
Over-oxidation of PRDXs has been linked to cell signaling through the “floodgate model,”
in which PRDXs consume low levels of endogenous peroxides, but enhanced generation leads to
over-oxidation/degradation and increase in H2O2 that acts as a second messenger [28]. Compared to
PRDX2, ANXA2 seems to be more resistant to oxidation during H2O2-dependent signaling [1,4]. In fact,
when we treated 293T cells with a high oxidative insult (100 µM of H2O2) we observed decreased
levels of PRDX2, while ANXA2 expression increased (Figure 3D). In these experiments we transfected
293T cells with the ANXA2-pcDNA3 plasmid to transiently express ANXA2 in these cells. It has been
previously shown that H2O2 induces the CMV promoter [29]. For this reason, it is likely that ANXA2
up-regulation in H2O2 treated cells is due at least in part to H2O2 induced CMV promoter activation.
Nevertheless, Madureira et al. have previously shown that the treatment of ANXA2 low expressing
cells, 293T and MCF7, with 100 µM H2O2 over a long period of time (two weeks) led to up-regulation
of ANXA2 in these cells [1].
4. Materials and Methods
4.1. Cell Culture, Transfections and Cell Lines
MDA-MB-231, A549, MCF7, MiaPaca2, HCT 116, U251, HEK 293, HT1080 and 293T cell lines were
obtained from ATCC and grown in DMEM (HyClone™, Pittsburgh, PA, USA) supplemented with 10%
fetal bovine serum (FBS), 20 mM L-Glutamine and 100 U/mL penicillin/streptomycin. TIME cells were
obtained from Dr McMahon and grown in EGM2 medium (Lonza, Basel, Switzerland) supplemented
with 2% FBS and 100 U/mL of penicillin/streptomycin. Cells were maintained in a humidified
incubator at 37 ◦C with 5% CO2. ANXA2 depleted cell lines and/or over-expressing H-RasV12 or
pBABE were obtained by transfection of Phoenix cells with 4 µg of the plasmids described on table SII,
using 8 µL of jetPRIME (Polyplus, Strasbourg, France) transfection reagent according to manufacturers’
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instructions. 48 h after transfection the target cells were infected with Phoenix supernatants and
selected with 2–5 µg/mL of puromycin for pSUPER-retro-puro or pBABE or 1 mg/mL neomycin for
pSUPER-retro-neo backbone plasmids. HT1080 and MDA-MB-231 ANXA2 KO cell lines were obtained
by tranfection of the WT cells with 3 µg of pANXA2-gRNA1-px459-V2 or pANXA2-gRNA2-px459-V2
using 6 µL of jetPRIME transfection reagent according to the manufacturers’ instructions. 48 h after
transfection the cells were selected with 5 µg/mL of puromycin. Serial dilutions were performed
to obtain HT1080 and MDA-MB-231 ANXA2 KO sub-populations. For transient transfection and
co-immunoprecipitation experiments, 293T cells in 6 wells plates were transfected for 24–48 h with 1
µg of either pcDNA3, pcDNA3-ANXA2, pcDNA3-ANXA-Cys-8-Ala, pcDNA3-ANXA-Cys-132-Ala,
pcDNA3-ANXA-Cys-334-Ala, pcDNA3.1-PTEN, pcDNA3.1-PTEN-Cys-124-Ser, or GFP-PTEN
plasmids, described below, using 2 µL (single plasmid transfection) or 4 µL (co-transfection) of
jetPRIME transfection reagent according to the manufacturers’ instructions.
4.2. Plasmids and Transfections
Construction of shRNA and CRISPR/Cas9 plasmids are described on Supplementary Materials
Table S2. Construction of pcDNA3-ANXA2, pcDNA3-ANXA2-Cys-8-Ala, pcDNA3-ANXA2-Cys-
132-Ala and pcDNA3-ANXA2-Cys-334-Ala plasmids is described in [1]. PTEN-Wt and PTEN-Cys-
124-Ser cDNAs were cloned into pcDNA3.1 vector at restriction sites BamHI/NotI to generate
pcDNA3.1-PTEN and pcDNA3.1-PTEN-Cys-124-Ser these plasmids were kindly provided by Dr.
Wolfgang Link. GFP-PTEN was a gift from Dr. Alonzo Ross (Addgene plasmid # 13039). The plasmids
pBabe-puro (1764) and pBabe-puro H-RasV12 (39526) were purchased from Addgene, Watertown,
MA, USA.
ANXA2 depleted cell lines and/or over-expressing H-RasV12 or pBABE were obtained by
transfection of Phoenix cells with 4 µg of the plasmids described on Supplementary Materials
Table S2, using 8 µL of jetPRIME (Polyplus) transfection reagent according to manufacturers’
instructions. 48 h after transfection the target cells were infected with Phoenix supernatants and
selected with 2–5 µg/mL of puromycin for pSUPER-retro-puro or pBABE or 1 mg/mL neomycin for
pSUPER-retro-neo backbone plasmids. HT1080 and MDA-MB-231 ANXA2 KO cell lines were obtained
by tranfection of the WT cells with 3 µg of pANXA2-gRNA1-px459-V2 or pANXA2-gRNA2-px459-V2
using 6 µL of jetPRIME transfection reagent according to the manufacturers’ instructions. 48 h after
transfection the cells were selected with 5 µg/mL of puromycin. Serial dilutions were performed
to obtain HT1080 and MDA-MB-231 ANXA2 KO sub-populations. For transient transfection and
co-immunoprecipitation experiments, 293T cells in 6 wells plates were transfected for 24–48 h with
1 µg of either pcDNA3, pcDNA3-ANXA2, pcDNA3-ANXA-Cys-8-Ala, pcDNA3-ANXA-Cys-132-Ala,
pcDNA3-ANXA-Cys-334-Ala, pcDNA3.1-PTEN, pcDNA3.1-PTEN-Cys-124-Ser, or GFP-PTEN
plasmids, described below, using 2 µL (single plasmid transfection) or 4 µL (co-transfection) of
jetPRIME transfection reagent according to the manufacturers’ instructions.
4.3. Antibodies
Antibodies are listed in Supplementary Materials Table S3.
4.4. Immunoprecipitation Assays
For co-immunoprecipitations, cells were washed with PBS, lysed with Triton X-100 lysis buffer
(50 mM Tris pH 7.5, 0.2% Triton X-100, 15 mM NaCl, 2 mM EGTA, 1 mM EDTA, protease inhibitors,
5 mM NaVO4, 10 mM NaF) degassed for 1 h. Cell lysates were incubated with specific antibodies
for 1 h at 4 ◦C and then pre-washed 50% slurry protein G-Sepharose™ (GE Healthcare, Pittsburgh,
PA, USA) was added for 1 h at 4 ◦C. Immunoprecipitates were washed four times with 300 µL of
lysis buffer, resuspended with 20 µL 2× SDS-PAGE loading buffer, boiled for 10 min, subjected to
SDS-PAGE and analyzed by western blotting.
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4.5. Western Blotting
Cells were treated as described in the results section and extracts were prepared with lysis buffer
(2 mM EGTA, 1 mM EDTA, 50 mM Tris pH 7.5, 120 mM NaCl, 0.1% Na deoxycholate, 1% NP-40, 10 mM
NaF, 5 mM NaVO4, protease inhibitors). For western blotting, 20 µg of each cell lysate was subjected
to SDS-PAGE, transferred onto a nitrocellulose membrane, incubated with appropriate antibodies and
visualized using ChemiDoc™ XRS (BioRad®, Watford, UK).
4.6. qRT-PCR
RNA was isolated using the RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions.
The gene expression was measured by qRT-PCR using the One-step NZYSpeedy RT-qPCR Green kit
(Nzytech, Lisbon, Portugal) according to manufacturer´s instructions in a Lightcycler 96 instrument
(Roche, Basel, Switzerland). Gene expression levels were normalized to RPLP0 mRNA using the
2−∆∆CT method [30]. Error bars represent the standard deviation obtained from average of triplicate
samples from three independent experiments. The primers used for qRT-PCR are on Supplementary
Materials Table S4.
4.7. Immunofluorescence Studies
Snap frozen tumors were sectioned on a cryostat and mounted on slides. Slides were fixed for
30 min using −20 ◦C cold methanol. Slides were incubated in a humidified chamber at 37 ◦C for
30 min with swine serum (Dako, Glostrup, Denmark). The serum was removed and the slides were
incubated with anti-ANXA2 (dil 1:500) and anti-PRDX2 (dil 1:500) for 1 h in a humidified chamber at
37 ◦C. After washing three times with PBS for 10 min at RT, slides were incubated with the appropriate
FITC-conjugated secondary antibodies in a humidified chamber at 37 ◦C for 1 h. After washing as
described above, chamber slides were mounted on glass cover slips using Vector mounting solution
for fluorescence (Vector Laboratories, UK) and viewed using a Zeiss LSM 510 META -Laser Scanning
Confocal Microscope (Carl Zeiss Inc., Oberkochen, Germany.
4.8. H&E Staining
Snap frozen tumors were sectioned using a cryostat and mounted on slides. Samples were
incubated in 95% alcohol for 2 min and 70% alcohol for 2 min. Afterwards they were washed briefly
in distilled water. Slides were immersed in Harris hematoxylin solution for 8 min and then washed
in running tap water for 5 min. After washing, slides were incubated in 1% acid alcohol for 30 s and
washed in running tap water for 1 min. Slides were incubated in 0.2% ammonia water for 45 s and
washed again in running tap water for 5 min. Slides were rinsed with 95% alcohol and counterstained
in eosin-phloxine B solution 1 min. Following incubation samples were dehydrated with 95% alcohol
for 5 min and two changes of absolute alcohol for 5 min. Slides were cleared by 2 changes of xylene for
5 min each. Slides were mounted with xylene based mounting medium (DAKO, Glostrup, Denmark)
and visualized using an optical microscope (Axiovert 40C, Carl Zeiss Inc., Oberkochen, Germany).
4.9. Clinical Samples Collection
Colon carcinoma samples were obtained from patients at the time of surgery. Patients´ consent
was obtained and the experiments conformed to the principles set out in the WMA Declaration of
Helsinki and the Department of Health and Human Services Belmont Report. Ethical approval was
obtained for each procedure from the Research Ethics Board, (VG Hospital, Halifax, Nova Scotia,
Canada; ethical code: CDHA-RS/2010-111, 17 September 2010).
4.10. Oxidative Stress RT2 PCR Profiler Array
1 × 106 cells were grown in 100 mm plates for 24 h. After what RNA was extracted using the
RNeasy Plus Mini Kit (Qiagen, Manchester, UK) according to the manufacturer´s instructions. RNA
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quality was analyzed using an RNA 6000 Nano Kit chip assay (Agilent, Santa Clara, CA, USA) in a
2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) to ensure RNA extracts had an integrity index value
greater than 9.0. Two µg of each RNA was used for cDNA synthesis using the RT2 first strand kit
(Qiagen, Manchester, UK) according to the manufacturer’s instructions. The RT2 Profiler™ PCR Array
Human Oxidative Stress; ref: PAHS-065Z (Qiagen, Manchester, UK) was performed according to the
manufacturer’s instructions in a LightCycler 96 instrument (Roche, Basel, Switzerland).
4.11. Statistical Analysis
The statistical significance was evaluated using two-tailed Student’s t-test. The p-values were
calculated from at least three independent experiments (n ≥ 3).
4.12. Supplementary Materials and Methods
Materials and Methods related to supplementary Figures are described in Appendix A.
5. Conclusions
Our data allowed us to propose the model depicted in Figure 6. In conclusion, we
provide mechanistic evidence that ANXA2 via its Cys-8 residue has a key role in positively
regulating PTEN to inhibit AKT phosphorylation at Ser473 activation site. The co-expression and
co-immunoprecipitation studies in conjunction with our observation that ANXA2 depleted cells show
enhanced phosphorylation of AKT following H2O2-dependent signaling compared to control cells
support that direct regulation of PTEN by ANXA2 might constitute an important mechanism in
regulating AKT phosphorylation following H2O2-dependent signaling (e.g., EGF/EGFR; Ras V12)
(Figure 6A). However we cannot rule out the possibility that other molecular mechanisms might be
involved in the regulation of AKT activity by ANXA2 during H2O2-dependent signaling. Activation
of the EGF/PI3K/AKT or RAS/PI3K/AKT networks enable Rac to bind to and activate NOX. This
ultimately drives the increase in intracellular H2O2 and potently induces the levels of the peroxiredoxin,
PRDX2 to compensate for the REDOX unbalance and buffer/inactivate the excess H2O2 (Figure 6B).
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Appendix A
Intracellular ROS Measurement: 2 × 104 cells/well were seeded in 96 wells plates and incubated
overnight at 37 ◦C. Cell medium was removed and cells were incubated with serum free medium for
16 h (MDA-MB-231, A549) or 6 h (HT1080). Cells were then incubated with 50 µM DCF-DA (SIGMA)
for 30 min at 37 ◦C, 5% CO2. After what fluorescence was measured (Excitation: 488 nm, Emission:
535 nm) using a fluorometer plate reader.
MTS Assay: 1 × 104 cells/well were seeded in 96 wells plates and incubated overnight at 37 ◦C.
After what cells were washed with PBS and incubated overnight (16 h) with serum free DMEM media.
Cells were then either not treated or treated with 15 nM EGF for 24 h. Cell proliferation was determined
using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI,
USA) according to the manufacturer’s instructions.
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